Today marks World Hormone Health Day—a timely opportunity to shine a light on a low-cost, under-discussed treatment that's transforming lives worldwide: Low Dose Naltrexone (LDN).
To coincide with this awareness day, we're excited to share, for the very first time, news of the upcoming release of The LDN Book 4: Chronic Pain and Autoimmune Disease, edited by international LDN pioneer Linda Elsegood, founder of The LDN Research Trust. The book will be officially published at the annual LDN Conference on June 6 2025.
This powerful new volume - the latest in the highly respected series - brings together real-life case studies and expert insights from leading international clinicians, showing how LDN is being used to manage a wide range of conditions—including endocrine disorders, Ehlers-Danlos Syndrome (EDS), autoimmune diseases, and mental health challenges.
Why this matters now:
- Chronic pain and hormonal imbalance affect millions globally—and effective, affordable treatments are urgently needed.
- LDN is increasingly being recognised by experts as a safe, non-addictive, and accessible option for patients failed by conventional treatments.
- With decades of research and thousands of patient stories behind it, LDN deserves a place in the public health conversation.
We are offering:
Digital review copies of The LDN Book 4 ahead of its June release Interviews with editor and LDN Research Trust founder Linda Elsegood (who uses LDN for MS) Access to doctors and patients from around the world who are ready to share their experiences with LDN
If you're planning content around Chronic Pain Awareness Month (May) or LDN Awareness Week (17-23 June)—we'd love to support you with compelling case studies and expert voices.
Please see the AI attached for more information.
Best regards,
Helen Lewis
Director
Literally - The Book Marketing & Author Branding Agency